Cargando…

Efficacy of early initiation of ivabradine treatment in patients with acute heart failure: rationale and design of SHIFT‐AHF trial

AIMS: Elevated heart rate (HR) in heart failure (HF) is associated with worse outcomes, particularly in acute HF (AHF). HR reduction with ivabradine reduces cardiovascular events in HF patients with reduced ejection fraction. The present trial aimed to test the hypothesis that the early HR reduction...

Descripción completa

Detalles Bibliográficos
Autores principales: Su, Yang, Ma, Teng, Wang, Zeyu, Dong, Bin, Tai, Chenhui, Wang, Hao, Zhang, Fenglei, Yan, Chunxi, Chen, Wei, Xu, Yawei, Ye, Lei, Tye, Gee Jun, Ong, Sang‐Bing, Zhang, Jian, Xu, Dachun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754724/
https://www.ncbi.nlm.nih.gov/pubmed/32945150
http://dx.doi.org/10.1002/ehf2.12997
_version_ 1783626249073065984
author Su, Yang
Ma, Teng
Wang, Zeyu
Dong, Bin
Tai, Chenhui
Wang, Hao
Zhang, Fenglei
Yan, Chunxi
Chen, Wei
Xu, Yawei
Ye, Lei
Tye, Gee Jun
Ong, Sang‐Bing
Zhang, Jian
Xu, Dachun
author_facet Su, Yang
Ma, Teng
Wang, Zeyu
Dong, Bin
Tai, Chenhui
Wang, Hao
Zhang, Fenglei
Yan, Chunxi
Chen, Wei
Xu, Yawei
Ye, Lei
Tye, Gee Jun
Ong, Sang‐Bing
Zhang, Jian
Xu, Dachun
author_sort Su, Yang
collection PubMed
description AIMS: Elevated heart rate (HR) in heart failure (HF) is associated with worse outcomes, particularly in acute HF (AHF). HR reduction with ivabradine reduces cardiovascular events in HF patients with reduced ejection fraction. The present trial aimed to test the hypothesis that the early HR reduction using ivabradine improves clinical outcomes in patients with AHF. METHODS AND RESULTS: SHIFT‐AHF is a prospective, multi‐centre, double‐blind, randomized, placebo‐controlled trial to evaluate the efficacy and safety of ivabradine when adding to standard therapy in AHF patients (SHIFT‐AHF). The trial will include 674 AHF patients with left ventricular ejection fraction < 45% and New York Heart Association functional classes III–IV. Participants were enrolled from March 2020 and will be followed up until December 2022. Patients are randomized to treatment with ivabradine or placebo (randomization 1:1). After allocation, the dose of ivabradine is titrated according to HR. Six months' follow‐up and three control visits (7, 90, and 180 days after enrolment) are required for every participant. Assessment involves clinical examination, laboratory tests, echocardiography, electrocardiography, heart rhythm, cardiac function, and quality of life. The primary endpoint is a composite of all‐cause mortality or re‐admission due to worsening HF. Secondary endpoints include the assessments of cardiac remodelling, cardiac functional capacity, and quality of life. CONCLUSIONS: The SHIFT‐AHF trial will shed further light on the role of early HR reduction using ivabradine in patients with AHF.
format Online
Article
Text
id pubmed-7754724
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-77547242020-12-23 Efficacy of early initiation of ivabradine treatment in patients with acute heart failure: rationale and design of SHIFT‐AHF trial Su, Yang Ma, Teng Wang, Zeyu Dong, Bin Tai, Chenhui Wang, Hao Zhang, Fenglei Yan, Chunxi Chen, Wei Xu, Yawei Ye, Lei Tye, Gee Jun Ong, Sang‐Bing Zhang, Jian Xu, Dachun ESC Heart Fail Study Designs AIMS: Elevated heart rate (HR) in heart failure (HF) is associated with worse outcomes, particularly in acute HF (AHF). HR reduction with ivabradine reduces cardiovascular events in HF patients with reduced ejection fraction. The present trial aimed to test the hypothesis that the early HR reduction using ivabradine improves clinical outcomes in patients with AHF. METHODS AND RESULTS: SHIFT‐AHF is a prospective, multi‐centre, double‐blind, randomized, placebo‐controlled trial to evaluate the efficacy and safety of ivabradine when adding to standard therapy in AHF patients (SHIFT‐AHF). The trial will include 674 AHF patients with left ventricular ejection fraction < 45% and New York Heart Association functional classes III–IV. Participants were enrolled from March 2020 and will be followed up until December 2022. Patients are randomized to treatment with ivabradine or placebo (randomization 1:1). After allocation, the dose of ivabradine is titrated according to HR. Six months' follow‐up and three control visits (7, 90, and 180 days after enrolment) are required for every participant. Assessment involves clinical examination, laboratory tests, echocardiography, electrocardiography, heart rhythm, cardiac function, and quality of life. The primary endpoint is a composite of all‐cause mortality or re‐admission due to worsening HF. Secondary endpoints include the assessments of cardiac remodelling, cardiac functional capacity, and quality of life. CONCLUSIONS: The SHIFT‐AHF trial will shed further light on the role of early HR reduction using ivabradine in patients with AHF. John Wiley and Sons Inc. 2020-09-18 /pmc/articles/PMC7754724/ /pubmed/32945150 http://dx.doi.org/10.1002/ehf2.12997 Text en © 2020 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Study Designs
Su, Yang
Ma, Teng
Wang, Zeyu
Dong, Bin
Tai, Chenhui
Wang, Hao
Zhang, Fenglei
Yan, Chunxi
Chen, Wei
Xu, Yawei
Ye, Lei
Tye, Gee Jun
Ong, Sang‐Bing
Zhang, Jian
Xu, Dachun
Efficacy of early initiation of ivabradine treatment in patients with acute heart failure: rationale and design of SHIFT‐AHF trial
title Efficacy of early initiation of ivabradine treatment in patients with acute heart failure: rationale and design of SHIFT‐AHF trial
title_full Efficacy of early initiation of ivabradine treatment in patients with acute heart failure: rationale and design of SHIFT‐AHF trial
title_fullStr Efficacy of early initiation of ivabradine treatment in patients with acute heart failure: rationale and design of SHIFT‐AHF trial
title_full_unstemmed Efficacy of early initiation of ivabradine treatment in patients with acute heart failure: rationale and design of SHIFT‐AHF trial
title_short Efficacy of early initiation of ivabradine treatment in patients with acute heart failure: rationale and design of SHIFT‐AHF trial
title_sort efficacy of early initiation of ivabradine treatment in patients with acute heart failure: rationale and design of shift‐ahf trial
topic Study Designs
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754724/
https://www.ncbi.nlm.nih.gov/pubmed/32945150
http://dx.doi.org/10.1002/ehf2.12997
work_keys_str_mv AT suyang efficacyofearlyinitiationofivabradinetreatmentinpatientswithacuteheartfailurerationaleanddesignofshiftahftrial
AT mateng efficacyofearlyinitiationofivabradinetreatmentinpatientswithacuteheartfailurerationaleanddesignofshiftahftrial
AT wangzeyu efficacyofearlyinitiationofivabradinetreatmentinpatientswithacuteheartfailurerationaleanddesignofshiftahftrial
AT dongbin efficacyofearlyinitiationofivabradinetreatmentinpatientswithacuteheartfailurerationaleanddesignofshiftahftrial
AT taichenhui efficacyofearlyinitiationofivabradinetreatmentinpatientswithacuteheartfailurerationaleanddesignofshiftahftrial
AT wanghao efficacyofearlyinitiationofivabradinetreatmentinpatientswithacuteheartfailurerationaleanddesignofshiftahftrial
AT zhangfenglei efficacyofearlyinitiationofivabradinetreatmentinpatientswithacuteheartfailurerationaleanddesignofshiftahftrial
AT yanchunxi efficacyofearlyinitiationofivabradinetreatmentinpatientswithacuteheartfailurerationaleanddesignofshiftahftrial
AT chenwei efficacyofearlyinitiationofivabradinetreatmentinpatientswithacuteheartfailurerationaleanddesignofshiftahftrial
AT xuyawei efficacyofearlyinitiationofivabradinetreatmentinpatientswithacuteheartfailurerationaleanddesignofshiftahftrial
AT yelei efficacyofearlyinitiationofivabradinetreatmentinpatientswithacuteheartfailurerationaleanddesignofshiftahftrial
AT tyegeejun efficacyofearlyinitiationofivabradinetreatmentinpatientswithacuteheartfailurerationaleanddesignofshiftahftrial
AT ongsangbing efficacyofearlyinitiationofivabradinetreatmentinpatientswithacuteheartfailurerationaleanddesignofshiftahftrial
AT zhangjian efficacyofearlyinitiationofivabradinetreatmentinpatientswithacuteheartfailurerationaleanddesignofshiftahftrial
AT xudachun efficacyofearlyinitiationofivabradinetreatmentinpatientswithacuteheartfailurerationaleanddesignofshiftahftrial